While the ECL assays detected slightly more ADA-positive patients than did the ELISA, these new ECL results support the conclusions established with ELISA that vedolizumab immunogenicity is low and has a minimal effect on vedolizumab PK or safety in patients with inflammatory bowel disease. Here, ADA is linked to inflammatory bowel disease.